Your browser doesn't support javascript.
loading
Evaluation of diabetic patients after three month use of continuous subcutaneous insulin infusion, dispensed by a protocolled form at outpatient reference clinic of Taguatinga Regional Hospital
Miranda, Leonardo Garcia; Pedrosa, Hermelinda Cordeiro; Falleiros, Roberta Kelly Menezes Maciel; Oliveira, Renata de Moraes; Tolentino, Monica; Casulari, Luiz Augusto.
  • Miranda, Leonardo Garcia; Taguatinga Regional Hospital. Research Centre. Brasília. BR
  • Pedrosa, Hermelinda Cordeiro; Taguatinga Regional Hospital. Research Centre. Brasília. BR
  • Falleiros, Roberta Kelly Menezes Maciel; Taguatinga Regional Hospital. Research Centre. Brasília. BR
  • Oliveira, Renata de Moraes; Taguatinga Regional Hospital. Research Centre. Brasília. BR
  • Tolentino, Monica; Taguatinga Regional Hospital. Research Centre. Brasília. BR
  • Casulari, Luiz Augusto; Taguatinga Regional Hospital. Research Centre. Brasília. BR
Arch. endocrinol. metab. (Online) ; 59(1): 23-28, 02/2015. tab
Article in English | LILACS | ID: lil-746442
ABSTRACT
Objective To evaluate the data of continuous subcutaneous insulin infusion protocol (CSII) for diabetics waived by the Health State Secretariat of Distrito Federal (HSSDF) and therapeutic responses three months after the transfer of multiple daily injections regimen for CSII. Subjects and methods Eighty patients (49 female) took part in this experimental study, mean age and disease duration were 27.9 years and 13 years, respectively; 96% patients had type 1 diabetes mellitus. Results The entire sample (ECO) and 3 subgroups (group 1 – A1c decrease, group 2 – A1c stable, and group 3 – A1c increase), stratified according to a ≥ 0.5% change in A1c, were analyzed. Group 1 involved 64% of the patients. The ECO showed a significant A1c decrease MDI 8.1 ± 1.4% vs. CSII 7.3 ± 0.9%, p < 0.0001 (0.8% difference pro CSII therapy). Group 1 demonstrated an A1c decrease from 8.7% to 7.3% (1.4% difference). Group 2 mean A1c was 7.1%. Rate of hypoglycemia (< 50 mg/dL) decreased 61% in the ECO and 79% in Group 2. Conclusion This study reinforces the safety and efficacy of CSII with a robust A1c reduction and hypoglycemia. The pioneer care HSSDF ambulatory attests to be achievable the free dispensing by Unified Health System (UHS) following a protocol, and this approach results in less wastage to the patient and represents a rational policy of therapy with CSII for UHS. Arch Endocrinol Metab. 2015;59(1)23-8 .
Subject(s)


Full text: Available Index: LILACS (Americas) Main subject: Diabetes Mellitus, Type 1 / Hypoglycemic Agents / Insulin Type of study: Evaluation studies / Practice guideline / Observational study Limits: Adolescent / Adult / Child / Female / Humans / Male Country/Region as subject: South America / Brazil Language: English Journal: Arch. endocrinol. metab. (Online) Journal subject: Endocrinology / Metabolism Year: 2015 Type: Article Affiliation country: Brazil Institution/Affiliation country: Taguatinga Regional Hospital/BR

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Index: LILACS (Americas) Main subject: Diabetes Mellitus, Type 1 / Hypoglycemic Agents / Insulin Type of study: Evaluation studies / Practice guideline / Observational study Limits: Adolescent / Adult / Child / Female / Humans / Male Country/Region as subject: South America / Brazil Language: English Journal: Arch. endocrinol. metab. (Online) Journal subject: Endocrinology / Metabolism Year: 2015 Type: Article Affiliation country: Brazil Institution/Affiliation country: Taguatinga Regional Hospital/BR